Cambridge Cognition Holdings PLC (AIM:COG) has launched a proprietary speaker identification system designed to prevent duplicate participant enrolment in clinical trials.
The AI-driven voice biometric tool will be deployed first by a large pharmaceutical customer in the fourth quarter of 2025, following initial commercial agreements.
The company said duplicate enrolment can undermine trial integrity, with published data suggesting up to 22% of participants take part in overlapping studies.
In the new system, voice recordings taken during trial visits will be compared with an enrolment database to verify identity before participation begins.
It is designed to be GDPR and HIPAA compliant, scalable across languages and applicable to multiple therapeutic areas.